The human papillomavirus (HPV) 9-valent, recombinant vaccine (Gardasil TM 9) helps protect young adults (males and females) against anogenital cancers and genital warts caused by certain HPV genotypes (ref. Gardasil TM 9 insert). This vaccine is administered intramuscularly (IM). The aim of this study was to determine preclinically whether intradermal (ID) vaccination with an unadjuvanted 9-valent recombinant HPV vaccine using a first-generation ID delivery device, the Nanopatch TM , could enhance vaccine immunogenicity compared with the traditional ID route (Mantoux technique). IM injection of HPV VLPs formulated with Merck & Co., Inc., Kenilworth, NJ, USA Alum Adjuvant (MAA) were included in the rhesus study for comparison. The Nanopatch TM prototype contains a high-density array comprised of 10,000 microprojections/cm 2 , each 250 mm long. It was hypothesized the higher density array with shallower ID delivery may be superior to the Mantoux technique. To test this hypothesis, HPV VLPs without adjuvant were coated on the Nanopatch TM , stability of the Nanopatch TM with unadjuvanted HPV VLPs were evaluated under accelerated conditions, skin delivery was verified using radiolabelled VLPs or FluoSpheres Ò , and the immune response and skin site reaction with the Nanopatch TM was evaluated in rhesus macaques. The immune response induced by Nanopatch TM administration, measured as HPVspecific binding antibodies, was similar to that induced using the Mantoux technique. It was also observed that a lower dose of unadjuvanted HPV VLPs delivered with the first-generation Nanopatch TM and applicator or Mantoux technique resulted in an immune response that was significantly lower compared to a higher-dose of alum adjuvanted HPV VLPs delivered IM in rhesus macaques. The study also indicated unadjuvanted HPV VLPs could be delivered with the first-generation Nanopatch TM and applicator to the skin in 15 s with a transfer efficiency of approximately 20%. This study is the first demonstration of patch administration in non-human primates with a vaccine composed of HPV VLPs.
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Introduction
Human papillomaviruses (HPV) are the major cause of cervical, vulvar, vaginal, penile, and anal cancers and are also responsible for genital warts [1] . Vaccines to prevent infection by HPV have been available since 2006, the most recent of which is GARDA-SIL TM 9, which was approved for prevention of certain cancers by the Food and Drug Administration (FDA) in December 2014, and offers protection from at least 9 HPV genotypes [2, 1]. It has been shown that adjuvanted HPV vaccines have been effective in prevention of HPV infection with genotypes 6, 11, 16, and 18 [3] . A 2-dose regimen of GARDASIL TM and GARDASIL TM 9 was approved in October 2016 by the FDA for use in boys and girls ages 9-14 years, and the age range for HPV immunization was recently expanded for men and women 27-45 years of age [4, 5] . Despite the effectiveness of the adjuvanted HPV vaccines, access and compliance remains to be improved [6, 7] . For example, uptake of adjuvanted HPV vaccines could be improved in rural areas of the United States and internationally, in less developed areas [8, 9] . As of 2014, in developed regions, 33.6% of females age 10-20 received the full HPV vaccine course as compared to 2.7% of females in the same age group from less developed regions [9] .
Adjuvanted HPV vaccines are administered to the muscle using a needle/syringe, and current data supports this route of delivery based on immunogenicity and efficacy studies [1] . In fact, the majority of vaccines are delivered intramuscularly (HepB, dTAP) or subcutaneously (measles, mumps, rubella, varicella).
One alternative to the current routes of vaccine delivery is administration to the skin. The work of Edward Jenner in the late 1700 0 s demonstrated that percutaneous delivery of smallpox or cowpox to the skin resulted in the development of protective immune responses against smallpox (reviewed in [10] ). The success of mounting a strong immune response by delivering vaccines to the skin is due to the population of immune cells present in this tissue. These include Langerhans cells in the epidermis as well as dermal dendritic cells [11] . There have been a number of publications that describe the role of these cells in mounting an immune response via the skin (reviewed in [12] ).
In addition to smallpox, several other vaccines have been demonstrated to mount an immune response when administered to the skin, and include recombinant hepatitis B virus vaccines (recombinant Hepatitis B surface antigen), influenza, rabies, and varicella [11, [13] [14] [15] [16] . There are several advantages to delivering these vaccines via the intradermal (ID) route. Recombinant Hepatitis B virus vaccines are delivered ID when an individual has not responded (''non-responders") to intramuscular injection of this vaccine [13] . HepB vaccines contain aluminum adjuvant. It has also been demonstrated that influenza and rabies vaccines can be administered ID at lower doses (i.e. ''Dose Sparing") when compared to IM administration and result in the same or similar immune response. For influenza, a range of 3-9 lg of each serotype (9-27 lg total) delivered ID is as effective as 15 lg (full dose) of each serotype delivered IM (45 lg total) [17] .
ID delivery with the rabies vaccine at 1/10th IM dose was as effective as the full-dose delivered IM [15] . With varicella, it was shown using the MicronJet TM intradermal delivery device that an immune response could be elicited in the skin and had the potential for dose sparing [16] . For these viral vaccines, an adjuvant is not required to elicit an immune response in the skin, muscle, or subcutaneously.
The traditional method of administering vaccines intradermally (ID) is the Mantoux technique, which utilizes a needle and syringe and requires a trained health care worker. Vaccine patches, which contain microprojections either coated with the vaccine or made of the vaccine itself, are another means to deliver vaccines to the skin. It has been recently shown in pre-clinical models that vaccines against influenza, measles, HPV, inactivated polio, and others have been administered to skin using various types of microneedle patches and Nanopatches TM [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . The Nanopatch TM pre-clinical vaccination studies in mouse and rat models demonstrated improved immunogenicity and/or significant dose-sparing (for a comparable immune response). The authors hypothesized that this may have been associated with a ''physical immune enhancer," in which the Nanopatch TM induces local cell disruption, leading to the release of cytokines, danger signals, and other immune-signaling molecules [33] . In the past few years, clinical studies, including one that utilized a next-generation Nanopatch TM and nextgeneration applicator prototypes delivering conventional influenza vaccines, have demonstrated that immune responses with intradermal patches are comparable with conventional IM delivery [34] [35] [36] .
In this report we investigated whether a high-density microprojection vaccine patch, the Nanopatch TM , could elicit an immune response in rhesus macaques using an unadjuvanted HPV vaccine as a model system. Previous studies evaluated the Nanopatch TM with unadjuvanted HPV VLPs in mice, which demonstrated an enhanced immune response when compared to the standard intramuscular route [30] . The authors hypothesized that application of a high-density array to the skin would produce a physical enhancer, which is distinct from standard intradermal delivery with a needle/syringe and would result in eliciting a systemic immune response that would have immediate (humoral) and long-term (memory) responses.
In this study, the first-generation Nanopatch TM and firstgeneration applicator prototypes were designed, tested, and evaluated in rhesus macaques, for the first time in a large animal model. The projections on the Nanopatch TM , each 250 mm in length, were designed to deliver vaccine to the epidermis and shallow dermis using an application system designed for use in large animal models. The version of the Nanopatch TM used in this rhesus study was different to that used in the subsequent clinical trials particularly in terms of the material used to manufacture the Nanopatch TM , as well as application conditions [34, 37] . To our knowledge, this is the first report of the evaluation of a high density microarray patch with an unadjuvanted HPV vaccine in a large animal model.
Materials and methods

Nanopatch
TM design, manufacture, and application Nanopatches TM for rhesus macaque studies were manufactured using the same method as previously described [38, 39] . Briefly, 6 in. silicon wafers were photolithographically patterned with SU8-2025 photoresist. Wafers were then etched by deep reactive ion etching (DRIE) to yield projections at 10,000 /cm 2 , each 250 mm in length. Nanopatches TM were diced to 10 X 10 mm and the edges bevelled to 45°, then Nanopatches TM were bonded to a polycarbonate backing, and quartered. A Nanopatch TM dosage form is a single 10 X 10 mm Nanopatch TM . The Nanopatches TM were quartered to ensure that any flex of the skin could be balanced with some flex of the Nanopatch TM . In the absence of quartering, the Nanopatches TM may have had the risk of cracking, and therefore quartering allowed the most efficient transfer of the antigen.
TM evaluation by Scanning Electron Microscopy Nanopatches TM were analyzed by scanning electron microscopy (SEM) as previously described [42] . SEM of coated and uncoated Nanopatches TM , and Nanopatches TM following application to rhesus skin was performed on a Philips XL30 SEM (45°tilt, 20 kV).
TM Proof-of-Principle 4 Applicator (PoP4)
Each Nanopatch TM was delivered using a custom applicator, PoP4 (Proof of Principle 4). PoP4 pushed the patches onto the site at a high speed ($15 m/s) to ensure full engagement of the Nanopatch TM surface with the skin [40, 41] . For Nanopatch TM delivery studies, the PoP4 applicator is first attached to the Nanopatch TM with holder, the Nanopatch TM is removed from the holder, placed against the skin, and the plunger activated to administer the Nano-patch TM to the skin. The Nanopatch TM is then removed. This firstgeneration applicator was designed only for preclinical use. . Following the coating procedure, Nanopatches TM were protected from the environment by placement into hinged boxes containing desiccant and then sealed in foil pouches with temperature monitors.
TM cold shipping studies Nanopatches TM were placed into individual hinged plastic containers containing dessicant, snap closed, and placed into foil pouches. The foil pouches contained both the hinged plastic containers and temperature monitoring devices (as described, Nanopatch TM vaccine coating). The foil pouches were placed with cold packs and shipped internationally. The temperature log therefore reflected the condition of the interior of the foil bags. Because the cold shipment was made over the course of approximately 2 weeks, and the temperature loggers were adjacent to the containers holding the Nanopatches TM , the temperature of the Nanopatches TM may have reached 2-8C during the shipment.
2.6. Nanopatch TM transfer efficiency studies in pig cadaver skin (Pig Ears)
To evaluate the transfer efficiency of unadjuvanted HPV VLPs that were coated on the Nanopatch TM , 54 lg of 14 C -labeled unadjuvanted HPV VLP genotype 11 was coated onto Nanopatches TM and applied using a PoP4 applicator to pig ears. This applicator was tested on pig ears prior to being utilized with rhesus macaques. To visually confirm that the Nanopatches TM engaged firmly and penetrated the surface of the skin, Coomassie blue was added to some of the Nanopatches TM . Following administration, the site of administration was swabbed to remove any material left on the skin surface, then cut out using a scalpel, digested overnight, placed in scintillation fluid, and counted on a scintillation counter. . The sites selected were the quadriceps (thigh), forearm, and inguinal areas. Rhesus macaques were sedated using Ketamine HCL (100 mg/mL) (Fort Dodge) prior to Nanopatch TM administration. Nanopatches TM were applied from fifteen seconds to two minutes and skin samples were then collected from the Nanopatch TM application area within 5 min after the Nanopatch TM was removed from the skin, and in sections that were marginally larger (several mm around the perimeter) than the Nanopatch TM application area. The twominute application had been established in previous applications to the mouse ear (data not shown), consistent with previous mouse studies with Nanopatches TM and non-adjuvanted HPV vaccine [30] . Transfer efficiency was determined by placing the tissue in scintillation fluid followed by counting using a scintillation counter.
Delivery of FluoSpheres
Ò into rhesus macaque skin (Rhesus study
#2)
To determine the depth of penetration of the microprojections into the skin of rhesus macaques, a FluoSphere Ò (ThermoFisher)
coating was used on the Nanopatches . Rhesus macaques were sedated using Ketamine HCL (100 mg/mL) (Fort Dodge) prior to Nanopatch TM administration. Nanopatches TM were applied for two minutes. Skin samples were then collected as described for Nanopatches TM coated with 14 C-labeled HPV genotype 11. Histological samples of the skin were prepared. Fluorescent microscopy images of skin sections following Nanopatch TM application were obtained using a 488 nm wavelength of light with a Aperio ScanScope slide scanner. Measurements in the skin were taken to determine the depth of delivery of FluoSpheres Ò at four different sites: the quadriceps, forearm, ear, and inguinal areas.
HPV VLP stability on Nanopatches
TM
Recombinant HPV VLPs were generated at Merck & Co., Inc., West Point, PA, USA. Unadjuvanted HPV VLPs were coated in Australia onto Nanopatches TM and were placed in holding containers and incubated at 25°C or 37°C. Potency of the HPV VLPs was determined by surface plasmon resonance (SPR) using the Biacore 2000 (GE Healthcare). The SPR method measures the amount of intact VLPs that bind to specific neutralizing monoclonal antibodies and is represented as a percent relative to a reference VLP lot. These antibodies recognize HPV VLPs that are intact and have the correct structure to elicit an immune response. The SPR method has been previously described [43] .
Rhesus macaque vaccination (Rhesus Study #3)
Rhesus macaque studies were performed in accordance with all animal ethics guidelines, and animal procedures were approved under the IACUC of Merck & Co., Inc., Kenilworth, NJ, USA. Animals were 4-5 years old and placed in groups of 6 that were gender-and weight-balanced, with individual weights ranging from 4.6 to 10.2 kg. Six animals per group were selected based on previous studies performed with HPV VLPs and rhesus macaques (data not shown). All animals had a negative titer for HPV prior to vaccination. Intradermal site preparation was performed by first using an Oster clipper with #40 blade to remove the coarse hair. Following this, an electric Remington shaver was used to remove hair from the surface prior to Nanopatch TM application or ID administration (Mantoux). Quadriceps sites were selected for immunization due to the ability to obtain consistent Nanopatch TM administration and large surface area. Vaccination was performed at 0 and 4 weeks and blood collected at 0, 4, and 8 weeks. Table 1 indicates the route, dose, method, and dose delivered of HPV VLPs utilized. Animals were sedated using Ketamine HCL (100 mg/mL) (Fort Dodge) prior to vaccine administration and blood collection. The Nanopatches TM supplied for the rhesus macaque study were coated with 70 lg of unadjuvanted HPV VLPs at the same ratio as described in the stability procedure. Following delivery, this yielded approximately 14 mg which is 1/5 the dose given IM.
HPV-specific IgG ELISA
For assessing HPV-specific humoral immune responses, sera were collected from immunized monkeys at 4 weeks (4 weeks post dose 1) and 8 weeks (4 weeks post dose 2). Endpoint ELISA was utilized to measure HPV specific total IgG titres. Briefly, 96 well plates were coated overnight at 4°C with a 4-valent mix of HPV-VLP (genotypes 6, 11, 16, 18) diluted in histidine buffer at 0.2 lg/ml each (total VLP concentration = 0.8 lg/ml). The four HPV genotypes that were tested were considered representative of the 9-valent vaccine that was administered. Plates were then washed and blocked with PBS + 1% BSA. Serum samples were then added to the plates starting with a 1:100 dilution followed by 3-fold serial dilutions and the plates incubated for 1.5 h at room temperature. After washing, peroxidase conjugated affinity-purified goat antimonkey IgG (gamma chain) (Rockland) was used as a secondary antibody at a 1:5000 dilution and incubated for 1 h at room temperature. Following a final wash, TMB substrate (Virolabs, VA) was added for 3-5 min, stopped with H 2 SO 4 , and plates were read using a PerkinElmer Envision plate reader that measured absorbance at 450 nm.
Statistical analysis
IgG titer values at 4 and 8 weeks were collected and log 10 -transformed with Graphpad Prism (Version 6.01, Graphpad Software, Inc.). Statistical analysis was performed using Tukey's multiple comparison's test with P-values obtained. A P-value < 0.05 is statistically significant.
Evaluation of skin following Nanopatch TM application
Prior to and following the application of Nanopatches TM , photographs of the sites were taken to assess any impact the application had on the surface of the rhesus skin.
Results
Nanopatches TM and vaccine coating
In preparation for the evaluation of an unadjuvanted HPV vaccine delivered ID in rhesus macaques, Nanopatches TM were fabricated using the deep reactive ion etching process and evaluated using scanning electron microscopy (SEM) with backscatter ( Fig. 1A, B) . These results demonstrated that consistent projections could be generated using this process (Fig. 1B) . Next, a few representative Nanopatches TM were coated using a gas-jet drying procedure with the coating solution and visualized by SEM with backscatter both prior to and following administration to rhesus skin (Fig. 1C, D) . The coating solution was the same as the one utilized with the 9-valent formulation for administration of the unadjuvanted HPV vaccine to rhesus macaques. This solution did not contain aluminum adjuvant. Fig. 1D depicts the Nanopatch TM following administration to rhesus skin, with light areas where vaccine is no longer present on the projections. Organic material such as the presence of a hair is shown remaining on the Nanopatch TM in darker contrast (Fig. 1D ). For coating the Nanopatch TM , a volume of 41 lL containing the targeted amount of antigen was applied to the Nanopatch TM and dried using the gas-jet approach (see Materials and Methods). All of the antigen was dried on the Nanopatch TM , which included both the projections and base of the Nanopatch TM . Following the coating and drying of unadjuvanted HPV VLPs in a formulation on individual Nanopatches TM , it was then determined whether the HPV VLPs maintained their potency. There was 73-93% recovery of HPV VLPs from Nanopatches TM following hydration of the patch surface with water. The concentration of the material eluted from the Nanopatch TM was also determined. The applicator, referred to as the Proof of Principle 4 (PoP4) applicator, used to administer the Nanopatch TM is shown in Fig. 2A . It consists of a spring-loaded plunger that connects to a Nanopatch TM which is held in a plastic holder. A Nanopatch TM in the plastic holder is depicted in Fig. 2B . Details on the use of the applicator are described in the Materials in Methods.
Nanopatch
TM cold shipping studies
Following the coating of Nanopatches TM with antigen, it was important to understand if the HVP VLP coating could withstand cold shipping. Nanopatches TM were coated with unadjuvanted HPV VLPs in Australia and cold shipped to the United States for evaluation/administration to cadaver pig skin (ears) or rhesus macaques (see Materials and Methods for packaging of the Nanopatches TM ). The storage and transport of vaccine coated Nanopatches TM to the site of Nanopatch TM administration had temperature and humidity ranges that are shown in Supplementary Fig. 1 . The temperature was maintained at approximately 0.5°C, with small excursions occurring during transport. A change in temperature and humidity was observed once the foil bag was opened and the temperature logging devices were exposed to ambient conditions (arrow, A, Supplementary Fig. 1 ). Additionally, a period of acclimatization to ambient conditions was also observed (arrow, B, Supplementary Fig. 1 ).
Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.jvacx.2019.100030. 
TM transfer efficiency studies in pig cadaver skin (Pig Ears)
Following evaluation of the cold shipping profile, the Nanopatches TM were evaluated in cadaver pig skin (ears) at both the site of Nanopatch TM coating, drying, and administration (Australia) under ambient conditions and following cold shipment of coated/dried Nanopatches TM and administration in the United States. These studies were performed to determine if a difference would be observed between Nanopatches (TM) that were coated/ dried and administered immediately vs. Nanopatches (TM) that were cold shipped then administered. In addition, because the rhesus Nanopatch TM studies (#1, #2, and #3, see Materials and Methods) would each be performed in one day, it was important to know if the Nanopatches TM would deliver the same amount of antigen at both the beginning and end of the day. This would also determine if any changes occurred to the applicator during this time period. Nanopatches TM that contained 14 C-labeled HPV VLPs and some which contained Coomassie blue (see Materials and Methods) were applied to pig ears using the PoP4 applicator. These Nanopatches TM contained a total of 54 lg unadjuvanted HPV VLPs. The results of the pig ear administration studies are depicted in Fig. 3 . The
14
C delivery results of applications to pig ears are shown as the two ''Before" groups with average delivery <30%, approximately 27% and 28% (CV of 14% and 6%) with and without Coomassie blue, respectively.
Immediately before commencement of the Rhesus #1 Study applications, Nanopatches TM from the batch were applied to defrosted pig ears to confirm that Nanopatches TM had not been detrimentally affected by cold shipping from Australia to the United States. These applications are the ''Start of Day" group in Fig. 3 . Two more defrosted pig ears were patched after the Rhesus #1 Study to confirm the consistency of the PoP4 applicator device throughout the day. These applications are the ''End of Day" group in Fig. 3 . Both the ''Start of Day" and ''End of Day" samples con- tained Coomassie blue. Following the experiments conducted in the United States, additional Nanopatch TM application to defrosted pig ears was conducted in Australia. The ''Retains" groups in Fig. 3 are samples from the study batch but retained in Australia and stored at 4°C. The ''Cold Shipped" samples were Nanopatches TM sent to the US but not used in the study and were cold shipped back to Australia for Nanopatch TM studies. The ''Fresh coated" group were not a part of the study and were coated after the study, using an identical formulation to the study batch as an experimental control. The results from all groups were consistent, despite the significant variations in environmental conditions experienced between some of the groups. All applications to pig ears were for two minutes. Percentage of delivery was calculated by dividing the amount of 14 C delivered to the skin (disintegrations per minute) by the amount of 14 C present on control Nanopatches TM (not applied to skin).
Delivery of vaccine into rhesus macaque skin
Following the completion of the cold shipping and delivery performance studies with the Nanopatch TM in pig ears, the release times and depth of delivery of material that was coated on the Nanopatch TM using rhesus skin were evaluated (Rhesus Study #1).
A study with 54 lg 14 C-labeled HPV genotype 11 coated on to Nanopatches TM was conducted to evaluate transfer efficiency with varied times of skin engagement and different locations in rhesus macaques (Fig. 4) . A range of different application times, from 15 s to 2 min, was evaluated at different sites (for additional details, see the Materials and Methods). These Nanopatches TM were administered to the thigh (quadriceps), forearm, and inguinal regions of two rhesus macaques using the PoP4 applicator (Rhesus Study #1, Fig. 4A, 4B ). It was determined in these studies that approximately 20-25% of 14 C-labeled HPV genotype 11 on the Nanopatch TM was delivered to the skin (Fig. 4A, 4B ). In another study, the amount of 14 C-labeled HPV genotype 11 from Nanopatches TM delivered to the skin site (quadriceps) ranging from 15 s to 2 min was performed (Fig. 4C) . These results indicated that the unadjuvanted HPV VLPs were delivered within approximately the first 15 s.
The next experiment was performed to evaluate the depth of delivery of material from the Nanopatch TM to rhesus skin (Rhesus Study #2). These experiments were performed by coating Nanopatches TM with FluoSpheres Ò . FluoSpheres Ò are particles that fluoresce following excitation at a wavelength of 488 nm, and histological sections containing the FluoSpheres Ò can be visualized by fluorescence microscopy (for additional details, see the Materials and Methods). Nanopatches TM coated with FluoSpheres Ò were delivered to the thigh (quadriceps), forearm, ear, and inguinal areas. The results indicated that FluoSpheres Ò are delivered to both the epidermis and dermis, and the penetration depth of projections in skin was on the order of $100 mm ± $20 mm (Fig. 5) . Penetration depth into ear skin was slightly deeper (Fig. 5B) . Despite the sites having substantially different subcutaneous tissue/muscle composition, there was no significant difference between the penetration depths achieved (Fig. 5B) .
Accelerated stability of nanopatches TM
Following the evaluation of vaccine delivery to the skin, accelerated stability of unadjuvanted HPV VLPs on the Nanopatch TM was 14 C labelled HPV type 11 Nanopatches TM were applied to pig ears. 'Before' samples with or without Coomassie blue (CB) were applied in Australia. 'Start of Day' indicates Nanopatches TM that were cold shipped and tested in the USA prior to administration for Rhesus study #1. 'End of Day' indicates evaluation of the Nanopatches TM at the conclusion of Rhesus study #1. 'Start' and 'End' of the day contained Coomassie blue. 'Retains' are the same batch of Nanopatches TM tested at Vaxxas (no shipping). 'Shipped' samples were Nanopatches TM sent to the USA under cold conditions and returned to Australia. The 'Fresh coated' group were not part of the study and were coated after the study, using an identical formulation to the study batch as an experimental control. Transfer efficiency on the quadriceps, forearm, and inguinal in two rhesus macaques, (C) Timed patch study and transfer efficiency on the quadriceps.
in Fig. 6 , and demonstrated that unadjuvanted HPV VLPs coated on the Nanopatch TM retained their functional stability over a period of 3 months at both 25⁰C and 37°C.
Immunogenicity study in rhesus macaques
Immunogenicity from unadjuvanted HPV VLPs delivered with the Nanopatch TM was next assessed (Rhesus Study #3). Table 1 (Fig. 7) . Blood was drawn to evaluate HPV-specific antibody responses by ELISA to a mixture of VLP genotypes 6, 11, 16 and 18 at 4 weeks post-dose 1 (Week 4) and 4 weeks post-dose 2 (Week 8), as depicted in Fig. 7 . The immune response to the benchmark IM dose of 70 lg HPV vaccine containing aluminum adjuvant was the strongest, as expected, and was statistically significant with a p value >0.001 when compared to the Nanopatch TM containing 70 lg unadjuvanted HPV VLPs. This was the only group that contained an adjuvant. The single Nanopatch TM loaded with 70 lg (approximately 14 lg delivered) had antibody titers similar to those induced by the Mantoux injection with 14 lg. These results suggest that the Nanopatch TM induces a comparable magnitude of HPV-specific antibodies using the same effective dose (14 lg)
when compared to the traditional Mantoux technique, and statistical differences between these groups were not observed using Tukey's multiple comparison's test (Fig. 7 and Table 2 ). Increasing the unadjuvanted HPV VLP dose by using two Nanopatches TM resulted in a higher trend in the IgG titer, however, it was similar to administration with a single Nanopatch TM and were statistically the same when comparing one Nanopatch TM with 70 lg unadjuvanted HPV VLPs to two Nanopatches TM each with 70 lg unadjuvanted HPV VLPs (Fig. 7 and Table 2 ). The immune response of two Nanopatches TM delivering 28 lg was similar to the response of the 70 lg dose delivered via the Mantoux technique, and were statistically equivalent (Fig. 7 and Table 2 ). There were no statistically significant differences in the immune response with unadjuvanted HPV VLPs either on the Nanopatch TM or Mantoux injection following post-prime or post-boost (data not shown).
The local skin reactogenicity of the Nanopatch TM was also evaluated following the dosing at Time 0 (Dose 1) and at 4 weeks (Dose 2), as shown in Fig. 8 . Close-up photographs of the skin from three rhesus macaques are depicted. Erythema and petechiae could be seen on the surface of the skin immediately following administration (Fig. 8) . Fig. 9 shows application sites from a rhesus 28 days after dose 1 which were representative. The monkeys were observed daily following application of the Nanopatch TM and no signs of pain or distress were observed.
Discussion
GARDASIL
TM and GARDASIL TM 9 for the prevention of HPV infection are administered intramuscularly. These vaccines are provided as liquids in pre-filled syringes (PFS) for easy administration to the patient as well as individual single-dose vials which are used with a needle/syringe for delivery, and are stored at 2-8°C. In this report, an unadjuvanted HPV vaccine (in the absence of aluminum adjuvant) in a dried form on a patch (Nanopatch TM ) for intradermal delivery, was investigated. Potential advantages of a vaccine patch compared to a liquid vaccine include the following: potential improved thermostability (dried vs. liquid), beneficial for needlephobic patients, removal/reduction of needles/sharps, and smaller footprint and weight.
The Nanopatch TM was coated using a gas-drying approach, in which 41 lL of the vaccine formulation was placed on the Nanopatch TM and dried using a stream of gas, as previously described [38] . One challenge with this method is that the vaccine formulation coats both the projections and base of the Nanopatch TM . Fig. 1 showed that areas of dark contrast, which correspond to the vaccine formulation, was present on the middle and lower portion of the projections, as well as the base. Areas of lighter contrast, corresponding to no vaccine formulation, was seen at the distal tips. This was one challenge with the gas-jet drying approach and may have resulted in the approximate 20% vaccine transfer efficiency to the skin, as any material on the base of the Nanopatch TM or bottom portions of the projections would likely not transfer vaccine to the skin.
It was demonstrated that the Nanopatch TM could be shipped cold internationally without impacting the amount of vaccine that was delivered from the Nanopatch TM to the skin, as shown from the Time 0 and shipped samples. Additionally, to ensure that the unadjuvanted HPV VLPs were structurally intact on the Nanopatches TM , accelerated thermostability experiments were performed at 25°C and 37°C. It was demonstrated that the dried HPV Nanopatch TM retained its potency at least 3 months at 37°C. When compared to the accelerated stability standards used for Vaccine Vial Monitors (VVM), 1 month at 37°C is equivalent to >4 years at 5°C.
Delivery studies of the Nanopatch TM in pig ears and rhesus macaque skin were performed with either 14 C-labeled HPV VLPs . Rhesus Study #3. ELISA of HPV-specific IgG titers induced by vaccination of rhesus macaques using Nanopatches TM compared to intramuscular injection (IM) or intradermal injection (Mantoux method), at doses delivered shown on the x axis. Doses for Nanopatch TM groups indicate the amount of HPV VLPs (total of 9 genotypes) that were delivered. The individual animal endpoint titers and the group geometric mean titers with 95% confidence intervals are plotted for each group at study week 4 (4 weeks post dose 1, red symbols) and study week 8 (4 weeks post dose 2, blue symbols). Titers of HPV-specific IgG antibodies that bind to a mixture of VLP genotypes 6, 11, 16 and 18 are defined as the reciprocal of the highest serum dilution that was detected at a level of two times the assay background. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) or FluoSpheres Ò . In both pig ears and rhesus skin, the delivery efficiency using 14 C-labeled HPV VLPs was approximately 20-25%, with the remainder not being delivered (remained on the Nanopatch TM ). This was a limitation of the Nanopatch TM coating approach at the time of the study which was based on earlier work in the mouse model, as mentioned [30] . Using 14 C-labeled HPV VLPs on the Nanopatch TM , it was demonstrated that the unadjuvanted HPV vaccine could be delivered within 15 s. Other Nanopatch TM vaccine coating methods (e.g. dip coating), increase the transfer efficiency to >85% [44] .
Data from the transfer studies for example, 15 s for antigen transfer, would be beneficial as it would reduce the possibility of the Nanopatch TM being removed or dislodged in the clinic when compared to an application time of 2 min. In pediatric populations, it would therefore be more advantageous to reduce the possibility of Nanopatch TM removal within the first 2 min. The evaluation of the site for Nanopatch TM administration is also a factor to consider when administering to specific populations (i.e. skin over the deltoid may be more accessible for young adult populations as compared with the thigh). These rapid release kinetics of the vaccine from the microprojections into the skin are broadly consistent with the fast release times observed when Nanopatches TM delivered conventional influenza vaccine into the skin of live mice [14] . It is believed the rapid dissolution is due to the fact that the high density array has a thin coating of vaccine (approximately one micron, data not shown) which allows rapid release into the skin.
Delivery of FluoSpheres Ò with the Nanopatch TM in rhesus skin demonstrated that the average depth of delivery was 100 mm and reached both the epidermis and dermis, thereby targeting the same strata as Nanopatch TM prototypes deployed to vaccinate mice and rats [30] [31] [32] .
The immunogenicity study to evaluate the HPV-coated Nanopatch TM in rhesus macaques demonstrated that antibody titers induced by the Nanopatch TM were at least comparable to ID injection using the Mantoux technique. With the exception of the 70 lg IM injection (needle/syringe with adjuvant) and Mantoux injections (needle/syringe without adjuvant), the doses delivered with the Nanopatch TM were not equivalent. This was a limitation of the study in that a number of Nanopatches TM would have needed to be applied to reach the 70 lg dose level used for IM and Mantoux injections. It did demonstrate that an immune response was mounted, however, the dose delivered was not considered dosesparing compared to IM delivery with an aluminum adjuvant. Other, lower density microneedle patches using pyramidal, dissolvable microneedles 600 mm in height and containing either measles or polio vaccine were also able to generate an immune response in rhesus macaques [18] [19] [20] . In the mouse model, administration of the Nanopatch TM , with a high density array and coated with HPV VLPs to the ear resulted in an enhanced immune response (statistically non-inferior to IM doses) [30] . The same response was not seen in the rhesus model, when tested for the potential for dose sparing at 14 and 28 lg unadjuvanted HPV VLPs.
There are a number of potential reasons why the Nanopatches (1) The amount of HPV delivered to the skin was lower than that administered IM (70 lg IM vs. 14 lg and 28 lg delivered with the Nanopatch TM ) and the IM dose contained an adjuvant, whereas the Nanopatch TM did not. (2) Rhesus skin has key physiological differences compared to the mouse or human. For example, the individual thickness of rhesus hair are greater than the thickness of human hair (follicles can be >150 mm in diameter), thus rhesus skin requires extensive preparation to remove coarse, dense hair from all skin sites. In this study, a high amount of stubble remained, and dye studies indicated that the stubble may have reduced Nanopatch TM /skin engagement. Also, the interaction between Nanopatches TM and the stubble potentially led to higher localized stresses in skin, thereby increasing petechiae and other skin damage. Skin strata are different in rhesus when compared to humans and the type and location of immune cells within rhesus skin is poorly understood. (3) The applicator used to apply the Nanopatch TM was a first generation design that likely utilized an excess of force for Nanopatch TM application. (4) The potential physical immune enhancer effect of Nanopatches TM , which was observed broadly in vaccination studies in both mice and rats, and a mode of action studied in mice, may not have been optimised in this first study scaling from small rodents to primates [28, [31] [32] [33] 45] .
Although anti-HPV IgG levels were substantial with both with the Nanopatch TM and Mantoux technique for intradermal administration, they were lower compared to intramuscular administration with aluminum adjuvant. Because the anti-HPV titer required to confer protection has not been determined, the clinical significance of the lower titers obtained with intradermal delivery is unknown [46] .
During the immunogenicity study, skin site reactions induced by HPV Nanopatch TM vaccination were evaluated. It was observed that the rhesus skin response at the quadriceps was quite marked due to the force of the application used in this study with the PoP4 applicator with a varied distribution in erythema (due to hair stubble) and clear petechiae. This was the first study undertaken with Nanopatches TM in an animal larger than a rodent or ferret. The PoP4 was the first applicator developed for this purpose and used a combination of speed and mass (plunger) to apply to the Nanopatch TM to the skin, extending a principle of Nanopatch TM application first developed in mice [44] . However, subsequent to the study reported here, a novel 'flying patch' approach has been pioneered that achieves Nanopatch TM engagement in the skin, but with reductions of energy of application by 10-100 fold [39] . Furthermore, because the Nanopatch TM alone makes contact with the skin (i.e. there is no plunger attached to it during skin contact), the energy of application is rapidly dissipated in the outer skin strata. This advanced, lower energy application approach has been applied to humans in clinical studies of Nanopatches TM [34, 37] . In this study, it was expected that the comparatively high energy of application was the cause of capillary damage and bruising at the application site in rhesus macaques immediately following application. Contrastingly, clinical studies with a similar Nanopatch TM design (density, area), but with the described 'flying patch' application condition (higher speed, lower overall force) showed a much-improved skin response with good patch-to-skin engagement, and a significant decrease in petechiae and coloration. This improvement from the PoP4 applicator to the newer applicator design therefore shows a lower amount of capillary damage and bruising and therefore has the potential for being more acceptable in a clinical setting. Additionally, this clinical application condition was preferred by subjects to intramuscular injection with a needle and syringe [34, 37] . As mentioned, a vaccine patch may be more advantageous for adolescents and teens who are not as routinely given vaccinations when compared to infants/toddlers and have less exposure to the needle/syringe. Therefore, the absence of the visibility of a needle has the potential to reduce anxiety for needle-phobic populations, or individuals that are not routinely given other vaccinations. Additionally, the potential for a more convenient, needle-free form of the HPV vaccine could be a patch image, such as the Nanopatch TM . Regions where uptake could be improved include rural areas of the United States and in Asia, Africa, and other regions [8, 9] .
Because the capillary damage and bruising was demonstrated to be minimal when compared to the PoP4 applicator, this may be more acceptable than the use of a needle/syringe. Additionally, it was shown that any capillary damage/bruising is no longer visible after 28 days following administration. While it is believed that the mode of action for the Nanopatch TM results in localized cellular damage to enhance the immune response, it is known from work in rodents that excessive cell death can move the systemic immune response away from the potential for a physical immune enhancer effect [31] .
There were a limited number of photographs taken post application due to the movement of the animals in their enclosures and the location of the application site. In most cases, at dose 2 (Day 28) in the majority of cases the previous application site (dose 1) was not visible. The animals were observed daily after application and again, there was no evidence that the application sites were causing the animals discomfort and there seemed to be no signs of scratching or itching. Photographs of IM injections to evaluate for erythema/edema were not taken as these sites were covered with hair. Mantoux injection sites were also not photographed.
In summary, it was demonstrated for the first time that a firstgeneration version of a high-density vaccine patch, the Nanopatch TM , when coated with an unadjuvanted HPV vaccine, could be maintained in a stable condition during cold shipping, retained potency under accelerated stability, could be delivered effectively, and could generate an immune response in non-human primates at least as well as ID delivery by the Mantoux method. 
